Reuters logo
BRIEF-Catalyst Biosciences' reports positive data on hemophilia B drug
September 6, 2017 / 12:23 PM / 3 months ago

BRIEF-Catalyst Biosciences' reports positive data on hemophilia B drug

Sept 6 (Reuters) - Catalyst Biosciences Inc

* Catalyst Biosciences announces positive factor ix clinical data

* Catalyst Biosciences-positive clinical data from 1st cohort of ongoing phase 1/2 proof-of-concept clinical trial in individuals with severe hemophilia b

* Catalyst Biosciences Inc - interim, top-line results of the open-label study are expected by end of 2017 and complete trial results in early 2018

* Catalyst Biosciences Inc - ‍ potency results are consistent with company’s earlier research​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below